Currently, over 90 percent of patients present with local or locoregional disease due to the widespread use of prostate cancer screening (i.e., use of prostate specific antigen [PSA] or digital rectal examination [DRE]). The gene discussed is KLK3; the disease is Familial prostate cancer.